Trial reportHaematologica2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Abstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.Blood advances · 2022Trial
- Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Trial
- Article
- Circulating tumor DNA in lymphoma: technologies and applications.Journal of hematology & oncology · 2025Review
- Application of interim PET-CT in first-line treatment decision-making for lymphoma.Journal of Zhejiang University. Science. B · 2023Review
- Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.Leukemia · 2022Review
- PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.Blood cancer journal · 2022Article
- Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.Phenomics (Cham, Switzerland) · 2022Review
- [Dose-enhanced immunochemotherapy followed by first-line autologous peripheral blood stem cell transplantation for young patients with high-risk aggressive B-cell lymphoma: an efficacy and prognostic factor analysis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.Blood advances · 2021Article
- PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.The British journal of radiology · 2021Review
- Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- The optimal use of PET/CT in the management of lymphoma patients.The British journal of radiology · 2021Review
- Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy.Clinical & translational immunology · 2021Article
- Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.Cell · 2019Article
- Article
- Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Review
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Mark HertzbergDepartment of Haematology, Prince of Wales Hospital and University of NSW, Randwick, NSW, Australia mhertzberg10@gmail.com.
Maher K GandhiThe University of Queensland Diamantina Institute Woolloongabba, Brisbane, QLD, Australia.
Judith TrotmanDepartment of Haematology, Repatriation General Hospital Concord and University of Sydney, NSW, Australia.
Belinda ButcherWriteSource Medical Pty Ltd., Lane Cove, NSW, Australia.
John TaperNepean Cancer Care Centre, Nepean Hospital Nepean, NSW, Australia.
Amanda JohnstonDepartment of Haematology, Westmead Hospital, NSW, Australia.
Devinder GillDepartment of Haematology, Princess Alexandra Hospital Brisbane, QLD, Australia.
Shir-Jing HoDepartment of Haematology, St George Hospital Kogarah, NSW, Australia.
Gavin CullDepartment of Haematology, Sir Charles Gairdner Hospital Perth, WA, Australia.
Keith FayDepartment of Haematology, Royal North Shore Hospital, St Leonard's, NSW, Australia.
Geoff ChongOlivia Newton John Cancer & Wellness Centre, Austin Hospital, Heidelberg, VIC, Australia.
Andrew GriggDepartment of Haematology, Austin Hospital, Heidelberg, VIC, Australia.
Ian D LewisDepartment of Haematology, Royal Adelaide Hospital Adelaide, SA, Australia.
Sam MillikenDepartment of Haematology, St Vincent's Hospital Darlinghurst, NSW, Australia.
William RenwickDepartment of Haematology, Royal Melbourne Hospital Parkville, VIC, Australia.
Uwe HahnDepartment of Haematology, The Queen Elizabeth Hospital, SA, Australia.
Robin FilshieDepartment of Haematology, St Vincent's Hospital Melbourne, VIC, Australia.
George KannourakisBallarat Oncology and Haematology Service and Fiona Elsey Cancer Research Institute, Ballarat, VIC, Australia.
Anne-Marie WatsonDepartment of Haematology, Liverpool Hospital, Liverpool, NSW, Australia.
Pauline WarburtonDepartment of Haematology, Wollongong Hospital, Wollongong, NSW, Australia.
Andrew WirthDepartment of Radiation Oncology, Peter MacCallum Cancer Centre East Melbourne, VIC, Australia.
John F SeymourDepartment of Haematology, Peter MacCallum Cancer Centre East Melbourne and University of Melbourne, Parkville, VIC, Australia.
Michael S HofmanDepartment of Cancer Imaging, Peter MacCallum Cancer Centre East Melbourne, VIC, Australia.
Rodney J HicksDepartment of Cancer Imaging, Peter MacCallum Cancer Centre East Melbourne, VIC, Australia.
Australasian Leukaemia Lymphoma Group (ALLG)
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the treatment of diffuse large B-cell lymphoma, a persistently positive [
Indexed as
Positron-Emission TomographyAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarmustineCyclophosphamideCytarabineDoxorubicinEtoposideFemaleFluorodeoxyglucose F18HumansIfosfamideAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedCarboplatinCarmustineCyclophosphamideCytarabineDoxorubicinEtoposideFluorodeoxyglucose F18ibritumomab tiuxetanIfosfamideMelphalanPodophyllotoxinPrednisoneR-CHOP protocolRituximabVincristine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.